“You can expect to hear more about our hematology assets at ASH later this year and about ARLDD at a medical conference early next year.”

In context

“lung cancer at ESMO. These data further strengthen our conviction in the potential of Krazati and the value it will add to our oncology portfolio. This builds on the previously granted fast-track designation from FDA for the idiopathic pulmonary fibrosis indication. These actions reinforce the potential importance of this asset in these diseases with high unmet medical need. Importantly, our CD19 NEX T cell therapy is making progress. We have started dosing patients in our LPA study and today I can disclose that we have now achieved clearance from the FDA to begin our MS trial. These are important milestones that illustrate our strategy of rapidly advancing cell therapies into immunologic diseases and becoming leaders in the space. We are moving forward with other assets in our pipeline. You can expect to hear more about our hematology assets at ASH later this year and about ARLDD at a medical conference early next year. Turning to business development, a key priority for capital allocation on Slide 9. As you know, BD has been a key component of our strategy to supplement our internal innovation. Our recently announced planned Mirati acquisition is an excellent example of a transaction with great strategic fit, compelling science, and financial soundness. Through this acquisition, we’re strengthening and diversifying our oncology portfolio with the addition of Krazati and potentially PRMT5, along with a pipeline of future KRAS inhibitors and enabling programs. We maintain significant cash flow to support continued investments in business development, and this will remain a top priority for capital allocation for the company. Turning now to our scorecard on Slide 10, I’ve already discussed many of the posi”